Clinical Trials · NCT01439542
FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Enrollment
- 19
- Start date
- Sep 2011
- Locations
- 1 site, Canada
- Primary endpoint
- Toxicity